RecruitingNot ApplicableNCT07367672

The Power of Belief: Expectation-driven and Placebo Modulation of Empathic Pain


Sponsor

University of Electronic Science and Technology of China

Enrollment

120 participants

Start Date

Dec 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This study investigates how belief and expectation influence empathic pain-the pain we feel when observing others in distress. Healthy adult participants will be randomly assigned to one of three groups: no-treatment control, placebo nasal spray, oxytocin-containing nasal spray. Participants in both the placebo and oxytocin conditions will be informed that they are receiving oxytocin, described as a potent agent for pain relief. During functional MRI scanning, all participants will view naturalistic pain-related videos and provide ratings of perceived subjective pain. The study aims to examine how cognitive beliefs and neuromodulatory interventions alter subjective pain experience and brain activity, including changes in brain network communication.


Eligibility

Min Age: 18 YearsMax Age: 30 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Intranasal Oxytocin (OT) 24 IU and a drug called Intranasal placebo administration for people with healthy participants. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 30 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIntranasal Oxytocin (OT) 24 IU

Administer oxytocin (24 IU) intranasally, 6 individual 0.1 ml puffs (4 IU/0. 1ml), three puffs per nostril one every 30 seconds. The participants will be informed that they are receiving oxytocin, described as a potent agent for pain relief.

DRUGIntranasal placebo administration

Administer placebo intranasally, 6 individual 0.1 ml puffs, three puffs per nostril one every 30 seconds. The participants will be informed that they are receiving oxytocin, described as a potent agent for pain relief.


Locations(2)

Weihua Zhao

Chengdu, Sichuan, China

University of Electronic Science and Technology of China

Chengdu, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07367672


Related Trials